Biallelic inactivation of NF2 represents the primary or sole oncogenic driver event in the vast majority of schwannomas; in addition, SH3PXD2A-HTRA1 fusions have been recently identified as an alternative oncogenic driver in a subset of sporadic schwannomas [1, 2]. Here, SH3PXD2A is linked to schwannoma.